» Articles » PMID: 26229609

Use of (99m)Tc 2-methoxyisobutyl Isonitrile in Minimally Invasive Radioguided Surgery in Patients with Primary Hyperparathyroidism: A Narrative Review of the Current Literature

Overview
Date 2015 Aug 1
PMID 26229609
Authors
Affiliations
Soon will be listed here.
Abstract

The use of technetium-99m 2-methoxyisobutyl isonitrile ((99m)Tc MIBI) for assistance in minimally invasive radioguided surgery (MIRS) is growing in popularity as a safe, effective, and proficient technique used for parathyroidectomy in primary hyperparathyroidism (PHPT) treatment. Previously, the preferred treatment for PHPT was bilateral neck exploration (BNE), a very invasive, costly, and lengthy procedure. However, as a large majority (80-85% of cases of PHPT) are attributed to a single parathyroid adenoma (PA), a simpler more direct technique such as MIRS is a far better option. The following article is an exploration of the current literature concerning varied protocols utilizing (99m)Tc MIBI for assistance in MIRS for patients undergoing treatment of PHPT. This technique boasts many advantageous outcomes for patients suffering from PHPT. These include a reduction in cost, operating time, and patient recovery; less evidence of post-surgical hypocalcaemia, less pain, and complications; superior cosmetic results; same-day discharge; and the possibility of local anaesthesia which is particularly beneficial in elderly patients. Better outcomes for patients with deep or ectopic PAs, reduced intra-operative complications, and improved cosmetic outcomes for patients who have previously undergone thyroid and/or parathyroid surgery are also advantageous. Of the literature reviewed it was also found that no patients suffered any major surgical complications such as laryngeal nerve palsy or permanent hypoparathyroidism using (99m)Tc MIBI for assistance in MIRS.

References
1.
Rubello D, Fig L, Casara D, Piotto A, Boni G, Pelizzo M . Radioguided surgery of parathyroid adenomas and recurrent thyroid cancer using the "low sestamibi dose" protocol. Cancer Biother Radiopharm. 2006; 21(3):194-205. DOI: 10.1089/cbr.2006.21.194. View

2.
Marx S . Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000; 343(25):1863-75. DOI: 10.1056/NEJM200012213432508. View

3.
Lal A, Bianco J, Chen H . Radioguided parathyroidectomy in patients with familial hyperparathyroidism. Ann Surg Oncol. 2006; 14(2):739-43. DOI: 10.1245/s10434-006-9254-y. View

4.
Rubello D, Massaro A, Cittadin S, Rampin L, Al-Nahhas A, Boni G . Role of 99mTc-sestamibi SPECT in accurate selection of primary hyperparathyroid patients for minimally invasive radio-guided surgery. Eur J Nucl Med Mol Imaging. 2006; 33(9):1091-4. DOI: 10.1007/s00259-006-0162-y. View

5.
Massaro A, Cittadin S, Rampin L, Banti E, Rossi F, Pelizzo M . Accurate planning of minimally invasive surgery of parathyroid adenomas by means of [(99m)Tc]MIBI SPECT. Minerva Endocrinol. 2007; 32(1):9-16. View